| Identification | Back Directory | [Name]
MW-150 | [CAS]
1628502-91-9 | [Synonyms]
MW-150
Pyridazine, 6-(4-methyl-1-piperazinyl)-3-(2-naphthalenyl)-4-(4-pyridinyl)- | [Molecular Formula]
C24H23N5 | [MDL Number]
MFCD32062790 | [MOL File]
1628502-91-9.mol | [Molecular Weight]
381.47 |
| Chemical Properties | Back Directory | [Boiling point ]
606.1±55.0 °C(Predicted) | [density ]
1.202±0.06 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [solubility ]
DMSO : 40 mg/mL (104.86 mM; Need ultrasonic) | [form ]
A solid | [pka]
7.16±0.42(Predicted) | [color ]
Off-white to light yellow | [InChI]
InChI=1S/C24H23N5/c1-28-12-14-29(15-13-28)23-17-22(19-8-10-25-11-9-19)24(27-26-23)21-7-6-18-4-2-3-5-20(18)16-21/h2-11,16-17H,12-15H2,1H3 | [InChIKey]
CIIVUDIZZJLXCN-UHFFFAOYSA-N | [SMILES]
C1(C2=CC=C3C(=C2)C=CC=C3)=NN=C(N2CCN(C)CC2)C=C1C1C=CN=CC=1 |
| Hazard Information | Back Directory | [Description]
MW-150 (MW01-18-150SRM) is a selective, orally active, neurotransmitter p38α MAPK inhibitor with a Ki of 101 nM. It inhibits the ability of endogenous p38α MAPK to phosphorylate the endogenous substrate MK2 in activated glia. | [Uses]
MW150 (MW01-18-150SRM) is a selective, CNS penetrant, and orally active inhibitor of p38α MAPK with a Ki of 101 nM. MW-150 inhibits the ability of the endogenous p38α MAPK to phosphorylate an endogenous substrate MK2 in activated glia[1]. | [Biological Activity]
MW-150 (MW01-18-150SRM) is a selective, orally active, neurotransmitter p38α MAPK inhibitor with a Ki of 101 nM. It inhibits the ability of endogenous p38α MAPK to phosphorylate the endogenous substrate MK2 in activated glia. | [in vivo]
MW-150 (2.5 mg/kg; oral daily for 3-4 months) improves the APP/PS1 transgenic (Tg) mice performance in radial arm water maze (RAWM) and contextual fear conditioning tests[1].
MW-150 (2.5 mg/kg; given i.p.; daily for 14 days) treatment in APPNLh/NLh × PSP264L/P264L knock-in mouse (with no overexpression of the amyloid precursor protein) exhibits RAWM behavior indistinguishable from WT mice[1]. | Animal Model: | APP/PS1 transgenic (Tg) mouse (overexpresses amyloid-beta)[1] | | Dosage: | 2.5 mg/kg | | Administration: | Oral daily; 3-4 months (until cognitive impairment is present) | | Result: | Improved the Tg mice performance in radial arm water maze (RAWM) and contextual fear conditioning tests. |
| [target]
| [IC 50]
p38α: 101 nM (Ki) | [storage]
Store at -20°C | [References]
[1] Roy SM, et al. Targeting human central nervous system protein kinases: An isoform selective p38αMAPK inhibitor that attenuates disease progression in Alzheimer's disease mouse models. ACS Chem Neurosci. 2015 Apr 15;6(4):666-80. DOI:10.1021/acschemneuro.5b00002 |
|
|